GlassScriptPhysician profile
Eric Duane Denny
NPI 1316436082
$3,869.90
in general payments reported to CMS, 2019-2025
19 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $926 · 2022: $616 · 2023: $1,287 · 2024: $791 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,506.21 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $407.55 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $403.67 | 2021-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $271.82 | 2021-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $269.79 | 2022-2024 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $239.29 | 2021-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $212.31 | 2023-2025 | Caplyta |
| Lundbeck LLC | $96.47 | 2021-2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $84.48 | 2022-2024 | Jornay Pm |
| Almatica Pharma LLC | $80.94 | 2024-2025 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $50.35 | 2021 | |
| Corium, LLC | $49.05 | 2021-2023 | Azstarys |
| Collegium Pharmaceutical, INC. | $43.47 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $34.81 | 2025 | |
| Alkermes, INC. | $31.45 | 2024 | Aristada, Lybalvi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $27.79 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $25.88 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $19.44 | 2023 | Quviviq |
| Eisai INC. | $15.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Denny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.